ArticleBMC microbiology2026
Characterization of tmexCD-toprJ-positive Klebsiella spp. from pediatric patients in a Chinese hospital.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe emergence of tmexCD-toprJ, a plasmid-mediated resistance-nodulation-division efflux pump gene cluster conferring resistance to tigecycline, poses a critical public health threat. While its prevalence among adults and within hospital settings has been extensively studied, its occurrence and epidemiological characteristics in pediatric populations remains scarcely reported and largely unknown.
resultsIn this study, a total of 2,344 clinical Klebsiella isolates collected from pediatric patients (2019–2025) were screened for tmexCD-toprJ using PCR, and five positive isolates were identified. Antibiotic susceptibility via broth microdilution confirmed that all five isolates were multidrug-resistant, including one isolate resistant to almost all tested antimicrobial classes. Whole-genome sequencing and bioinformatics analysis were conducted to determine their genetic contexts. These strains were assigned to four distinct sequence types (STs): ST15, ST571, ST750-1LV, and ST3520-1LV, and exhibited diverse capsular locus types. Beyond tmexCD-toprJ, the five isolates also harbored carbapenemase genes (blaNDM−1, blaNDM−5, blaIMP−4, and blaOXA−1) and other antimicrobial resistance genes. The tmexCD-toprJ gene cluster was located on plasmids belonging to various incompatibility groups, including IncHI1B/IncFIB/IncR/IncN, IncHI1B/IncFIB, IncX3, and IncHI1B/IncFIB (Mar). However, conjugation assays demonstrated that these tmexCD-toprJ-carrying plasmids were non-transferable to the Escherichia coli recipients under the tested conditions.
conclusionsTaken together, this study reports the concerning co-harboring of tmexCD-toprJ with carbapenemase genes and other resistance determinants in Klebsiella spp. isolates recovered from pediatric patients in China. The presence of these resistance mechanisms on diverse genomic backgrounds highlights a significant clinical risk and underscores the urgent need for enhanced genomic surveillance and targeted strategies to preserve tigecycline efficacy in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.